Wilmary Rodriguez Collado, MD
Pulmonary Disease · College Station, TXNPI 1750582573
Payments from drug & device makers
Across 17 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viatris Specialty LLC$100
- AstraZeneca$68
- Boehringer Ingelheim$51
- 3b Medical, Inc.$35
- Harmony Biosciences LLC$33
- Axsome Therapeutics, Inc.$33
- plus $181 from 8 others
What the payments were for
- Food & beverage$501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viatris Specialty LLC | 1 | $100 |
| AstraZeneca | 3 | $68 |
| Boehringer Ingelheim | 2 | $51 |
| 3b Medical, Inc. | 1 | $35 |
| Harmony Biosciences LLC | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Merck | 1 | $27 |
| Mylan Specialty L.p. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| GSK | 1 | $24 |
| United Therapeutics Corporation | 1 | $23 |
| Insmed, Inc. | 1 | $15 |
| Resmed Corp | 1 | $14 |
How this compares
$501 in reported general payments places this provider in the 25th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 411 | $344,961 |
| OpsumitMacitentan | 15 | $191,747 |
| OfevNintedanib Esylate | 14 | $181,550 |
| Spiriva RespimatTiotropium Bromide | 139 | $94,750 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 82 | $35,726 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $34,704 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $31,780 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $24,866 |
| Advair HfaFluticasone Propion/Salmeterol | 61 | $22,780 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $16,327 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 49 | $14,805 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $14,031 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $13,779 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $8,899 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 238 | $8,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $24 | $434,128616 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $51 | $306,407195 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $29 | $191,74715 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $68 | $59,57099 claims |
| MerckDulera | $27 | $5,10016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in College Station
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.